Literature DB >> 16568154

Diabetic cardiomyopathy: where are we 40 years later?

V Sharma1, John H McNeill.   

Abstract

Diabetic cardiomyopathy is a cardiac disease that arises as a result of the diabetic state, independent of vascular or valvular pathology. It manifests initially as asymptomatic diastolic dysfunction, which progresses to symptomatic heart failure. The compliance of the heart wall is decreased and contractile function is impaired. The pathophysiology is incompletely understood, but appears to be initiated both by hyperglycemia and changes in cardiac metabolism. These changes induce oxidative stress and activate a number of secondary messenger pathways, leading to cardiac hypertrophy, fibrosis and cell death. Alterations in contractile proteins and intracellular ions impair excitation-contraction coupling, while decreased autonomic responsiveness and autonomic neuropathy impair its regulation. Extensive structural abnormalities also occur, which have deleterious mechanical and functional consequences.

Entities:  

Mesh:

Year:  2006        PMID: 16568154      PMCID: PMC2560522          DOI: 10.1016/s0828-282x(06)70914-x

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  14 in total

Review 1.  Diabetic cardiomyopathy.

Authors:  David S H Bell
Journal:  Diabetes Care       Date:  2003-10       Impact factor: 19.112

2.  New type of cardiomyopathy associated with diabetic glomerulosclerosis.

Authors:  S Rubler; J Dlugash; Y Z Yuceoglu; T Kumral; A W Branwood; A Grishman
Journal:  Am J Cardiol       Date:  1972-11-08       Impact factor: 2.778

3.  Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion.

Authors:  A E Bielawska; J P Shapiro; L Jiang; H S Melkonyan; C Piot; C L Wolfe; L D Tomei; Y A Hannun; S R Umansky
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

4.  The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism.

Authors:  F Djouadi; J M Brandt; C J Weinheimer; T C Leone; F J Gonzalez; D P Kelly
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1999 May-Jun       Impact factor: 4.006

5.  Deficiency of cardiac beta-adrenergic receptor in streptozocin-induced diabetic rats.

Authors:  Y Nishio; A Kashiwagi; Y Kida; M Kodama; N Abe; Y Saeki; Y Shigeta
Journal:  Diabetes       Date:  1988-09       Impact factor: 9.461

Review 6.  Oxidative stress and stress signaling: menace of diabetic cardiomyopathy.

Authors:  Loren E Wold; Asli F Ceylan-Isik; Jun Ren
Journal:  Acta Pharmacol Sin       Date:  2005-08       Impact factor: 6.150

7.  Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha.

Authors:  J M Brandt; F Djouadi; D P Kelly
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

Review 8.  Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Authors:  Zhi You Fang; Johannes B Prins; Thomas H Marwick
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

9.  Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure.

Authors:  Peter Razeghi; Martin E Young; Tonya C Cockrill; O Howard Frazier; Heinrich Taegtmeyer
Journal:  Circulation       Date:  2002-07-23       Impact factor: 29.690

Review 10.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

View more
  9 in total

1.  The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.

Authors:  T Radovits; T Bömicke; G Kökény; R Arif; S Loganathan; K Kécsán; S Korkmaz; E Barnucz; P Sandner; M Karck; G Szabó
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

2.  Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCβ2.

Authors:  Hesham Soliman; Anthony Gador; Yi-Hsuan Lu; Guorong Lin; Girish Bankar; Kathleen M MacLeod
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-03       Impact factor: 4.733

3.  Expression of cardiac insulin signalling genes and proteins in rats fed a high-sucrose diet: effect of bilberry anthocyanin extract.

Authors:  Shamjeet Singh; Thomas Netticadan; D Dan Ramdath
Journal:  Genes Nutr       Date:  2016-03-17       Impact factor: 5.523

4.  Zingerone alleviates the delayed ventricular repolarization and AV conduction in diabetes: Effect on cardiac fibrosis and inflammation.

Authors:  Hany M El-Bassossy; Wafaa S Al-Thubiani; Ahmed A Elberry; Mohammad I Mujallid; Salah A Ghareib; Ahmad S Azhar; Zainy M Banjar; Malcolm L Watson
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

Review 5.  Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients.

Authors:  Jovana Nikolajević Starčević; Miodrag Janić; Mišo Šabovič
Journal:  Int J Mol Sci       Date:  2019-03-09       Impact factor: 5.923

6.  Increased Expression of Lipid Metabolism Genes in Early Stages of Wooden Breast Links Myopathy of Broilers to Metabolic Syndrome in Humans.

Authors:  Juniper A Lake; Michael B Papah; Behnam Abasht
Journal:  Genes (Basel)       Date:  2019-09-25       Impact factor: 4.096

7.  Predictors and prevention of diabetic cardiomyopathy.

Authors:  Vishalakshi Chavali; Suresh C Tyagi; Paras K Mishra
Journal:  Diabetes Metab Syndr Obes       Date:  2013-04-11       Impact factor: 3.168

Review 8.  The influence of diabetes on cardiac beta-adrenoceptor subtypes.

Authors:  V Melih Altan; Ebru Arioglu; Sahika Guner; A Tanju Ozcelikay
Journal:  Heart Fail Rev       Date:  2007-03-16       Impact factor: 4.654

9.  The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.

Authors:  Csaba Mátyás; Balázs Tamás Németh; Attila Oláh; László Hidi; Ede Birtalan; Dalma Kellermayer; Mihály Ruppert; Sevil Korkmaz-Icöz; Gábor Kökény; Eszter Mária Horváth; Gábor Szabó; Béla Merkely; Tamás Radovits
Journal:  Cardiovasc Diabetol       Date:  2015-10-31       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.